市场调查报告书
商品编码
1402484
欧洲左心室辅助装置市场预测至 2028 年 - 区域分析 - 依流程类型、设计与应用Europe Left Ventricular Assist Device Market Forecast to 2028 - Regional Analysis - by Type of Flow, Design, and Application |
欧洲左心室辅助装置市场预计将从2022年的3.3652亿美元成长到2028年的4.4505亿美元。预计2022年至2028年CAGR为4.8%。
LVAD 中人工智慧和机器学习的使用增加推动欧洲左心室辅助设备市场
与 LVAD 相关的併发症和不良事件发生率的增加鼓励製造商开发创新技术并将新技术整合到设备中。在某些情况下,使用 LVAD 装置的患者会出现右心室衰竭,导致静脉积血和肿胀。为了减少故障,製造商整合了人工智慧 (AI),透过 LVAD 监测右心室。因此,右心室活动和功能的任何变化都将报告给医疗保健专业人员,从而减少右心室衰竭和併发症的机会。
此外,越来越多地使用机器学习(ML)来制定心臟衰竭死亡率的风险评分,这比传统方法具有优势。此外,穿戴式装置的遥测资料分析有助于预测心臟衰竭住院。机器学习演算法用于获取 2D 和 3D 超音波心动图上的三尖瓣环偏移,这有助于评估右心室功能。此外,基于机器学习的演算法使用 3D 超音波心动图影像来研究右心室容积和射血分数,提供准确的资料和高效的心臟功能自动分析。
因此,利用人工智慧和机器学习演算法有助于开发基于左心室辅助功能的末期心臟衰竭患者右心室功能的风险预测模型。右心室衰竭的风险分层是帮助确定患者存活的重要因素之一。因此,在预测期内,在 LVAD 中使用人工智慧和机器学习很可能成为左心室辅助装置 (LVAD) 市场的主要趋势。
欧洲左心室辅助装置市场概况
英国国会的资料显示,2019年英国总人口中约有五分之一年龄在65岁及以上。而且,2009年至2019年间,该年龄层人口数量增加了23%,而英国总人口则增加了同期仅7%。 65岁或以上的人是心血管疾病和心臟衰竭的高发生率。随着心臟衰竭盛行率的增加,英国心臟移植的等待名单很长。根据英国心臟基金会的研究,2019年英国约有300人患有LVAD,而2012年只有约100人患有LVAD。根据英国老年医学会提供的资料,2020年,~英国有100 万人患有心臟衰竭,约5% 因紧急情况入院的人患有心臟衰竭。 2020 年,国家医疗服务 (NHS) 总支出的约 2% 用于心臟衰竭的治疗。心臟衰竭盛行率的激增正在推动英国 LVAD 市场的成长。
欧洲左心室辅助装置市场收入及 2028 年预测(百万美元)
欧洲左心室辅助装置市场细分
欧洲左心室辅助装置市场按流程类型、设计、应用和国家进行细分。
根据血流类型,欧洲左心室辅助装置市场分为脉动血流和非脉动血流。 2022年,非脉动血流细分市场在欧洲左心室辅助装置市场中占有更大份额。
根据设计,欧洲左心室辅助装置市场分为植入式心室辅助装置和经皮心室辅助装置。 2022年,植入式心室辅助装置细分市场在欧洲左心室辅助装置市场中占有更大份额。
根据应用,欧洲左心室辅助装置市场分为移植桥樑、目的地治疗、恢復桥樑和候选桥樑。 2022年,目的地治疗细分市场在欧洲左心室辅助装置市场中占最大份额。
根据国家/地区,欧洲左心室辅助装置市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2022年,英国在欧洲左心室辅助装置市场中占最大份额。
Abbott Laboratories、Medtronic Plc、Evaheart Inc. 和 CorWave SA 是欧洲左心室辅助装置市场上的一些领先公司。
The Europe left ventricular assist device market is expected to grow from US$ 336.52 million in 2022 to US$ 445.05 million by 2028. It is estimated to grow at a CAGR of 4.8% from 2022 to 2028.
Increased Use of Artificial Intelligence and Machine Learning in LVAD Drive Europe Left Ventricular Assist Device Market
The increased incidence of complications and adverse events associated with LVAD encouraged manufacturers to develop innovative technologies and integrate new technologies into the devices. In several cases, patients with LVAD devices experience right ventricle failure leading to blood buildup in veins and swelling. To reduce the failure, manufacturers have integrated artificial intelligence (AI) to monitor the right ventricle with LVAD. Therefore, any change in the right ventricle activity and function will be reported to the healthcare professional, reducing the chances of right ventricle failure and complications.
Furthermore, the increased use of machine learning (ML) for developing risk scores for heart failure mortality provides an edge over conventional methods. Additionally, telemetry data analysis from wearable devices helps predict heart failure hospitalizations. Machine learning algorithms are used to access tricuspid annulus excursion on 2D and 3D echocardiography, which helps in the assessment of right ventricle function. Moreover, machine learning-based algorithms use 3D echocardiographic images to study the right ventricle volume and ejection fraction, providing exact data and efficient automated analysis of heart function.
Therefore, the use of artificial intelligence and machine learning algorithms helps develop a risk prediction model based on right ventricle functions in end-stage heart failure patients with LVAD. The risk stratification for right ventricle failure is one of the significant factors that help determine the patients' survival. Therefore, the use of artificial intelligence and machine learning in LVAD is likely to emerge as a key trend in the left ventricle assist devices (LVAD) market during the forecast period.
Europe Left Ventricular Assist Device Market Overview
According to the UK Parliament's data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Moreover, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. People aged 65 or above are highly prone to cardiovascular diseases and heart failure. With the increasing prevalence of heart failure, the waiting list for heart transplantation is long in the UK. According to a study by the British Heart Foundation, ~300 people were living with LVAD in the UK in 2019, while only ~100 people were living with LVAD in 2012. According to the data provided by the British Geriatrics Society, in 2020, ~1 million people in the UK were living with heart failure, and ~5% of the people admitted to hospitals for emergencies were suffering from heart failure. In 2020, ~2% of the total National Health Service (NHS) expenditure is spent on treatment of heart failure. A surge in the prevalence of heart failure is propelling the growth of the LVAD market in the UK.
Europe Left Ventricular Assist Device Market Revenue and Forecast to 2028 (US$ Million)
Europe Left Ventricular Assist Device Market Segmentation
The Europe left ventricular assist device market is segmented into type of flow, design, application, and country.
Based on type of flow, the Europe left ventricular assist device market is bifurcated into pulsatile flow and non-pulsatile flow. In 2022, the non-pulsatile flow segment registered a larger share in the Europe left ventricular assist device market.
Based on design, the Europe left ventricular assist device market is bifurcated into implantable ventricular assist devices and transcutaneous ventricular assist devices. In 2022, the implantable ventricular assist devices segment registered a larger share in the Europe left ventricular assist device market.
Based on application, the Europe left ventricular assist device market is segmented into Bridge to transplantation, destination therapy, bridge to recovery, and bridge to candidacy. In 2022, the destination therapy segment registered the largest share in the Europe left ventricular assist device market.
Based on country, the Europe left ventricular assist device market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe left ventricular assist device market.
Abbott Laboratories, Medtronic Plc, Evaheart Inc., and CorWave SA are some of the leading companies operating in the Europe left ventricular assist device market.